The high-prosperity domestic substitution of the pharmaceutical industry boosts the pharmaceutical machinery industry to usher in a new round of growth

Recently, many pharmaceutical equipment companies have released three quarterly reports, many of which have exceeded expectations and doubled their net profit growth
.
Take Chutian Technology as an example.
In the first three quarters, it achieved a net profit of 401 million yuan attributable to shareholders of listed companies, a year-on-year increase of 723.
53%, and its net profit reached twice the full-year net profit of 2020
.
It is worth noting that in the third quarter alone, Chutian Technology achieved a net profit of 165 million yuan attributable to shareholders of listed companies, an increase of 413.
91% year-on-year, maintaining high growth
.
According to its current development trend, relevant people predict that Chutian Technology has sufficient orders in hand, and the performance of the fourth quarter and subsequent quarters is expected to maintain high growth
.
For many companies' performance increase, the analysis believes that this is mainly due to the high prosperity of the downstream pharmaceutical market and the continuous acceleration of domestic substitution
.
At present, as a whole, China's pharmaceutical industry has begun to accelerate its development mode, and the demand for pharmaceutical equipment is further released in the background, which is also injecting new growth momentum into the development of the pharmaceutical equipment industry
.
It is worth mentioning that in the face of the current blue ocean of the new market, many domestic pharmaceutical equipment companies have smelled opportunities.
In order to accelerate the increase of market share, they are adopting new methods such as mergers and acquisitions, increasing R&D investment, and focusing on talent team training.
Continue to work hard to improve their competitiveness and superior position, and it is expected that the performance will be affected for the first time
.
However, due to the late start of the industry and relatively weak experience, the current domestic pharmaceutical equipment mainly serves the domestic market, and few local companies are involved in the international market
.
According to data, the average export ratio of domestic pharmaceutical special equipment manufacturing is relatively low.
Based on the gross estimate of “cumulative export delivery value/cumulative main business income”, the average value since 2018 is 9%
.
The analysis believes that this may be related to the unsound overseas sales and promotion channels and low product maturity
.
However, under the background of fierce competition in the domestic market, some domestic pharmaceutical machinery companies continue to strengthen their business expansion, accumulate sales cases in traditional pharmaceutical equipment such as injection equipment, and continuously improve the quality of equipment, import substitution of domestic equipment, and internationalization.
Accelerated development
.
According to the author’s understanding, in recent years, the standards in the pharmaceutical equipment industry have been continuously improved, and policies to encourage and support the development of high-end pharmaceutical equipment have been continuously promulgated.
Machinery companies are seizing market opportunities, increasing R&D investment year by year, and at the same time paying more attention to personnel training and team building, and striving to improve the innovation level of domestic medical equipment
.
Based on the above, the industry believes that the pharmaceutical equipment industry has ushered in a new round of growth
.
In the future, with the acceleration of domestic substitution, international breakthroughs, and the rapid development of the biopharmaceutical industry, the pharmaceutical industry's demand for high-end pharmaceutical equipment will continue to grow
.
Affected by this, the performance of the pharmaceutical equipment industry will also have more room for imagination, and it may exceed 50 billion yuan in 2025
.